MilliporeSigma Launches Industry’s First Off-the-Shelf Cell Culture Media for Perfusion Processes
- Increases manufacturing flexibility
- Exceptional performance and consistency required for high-density perfusion cell culture processes
Billerica, Massachusetts, May 15, 2017 – MilliporeSigma today took a significant step toward increasing manufacturing flexibility and enabling higher productivity with the launch of the EX-CELL® Advanced™ HD Perfusion Medium. This first off-the-shelf, high-density cell culture media supports perfusion processes and facilitates high productivity at low perfusion rates, increasing production yield and speed to clinic.
Biomanufacturers are moving toward perfusion processes, the next generation in manufacturing, as they seek to cut costs while increasing quality and efficiency. Perfusion processes, however, require a new type of medium to facilitate high productivity at low perfusion rates. MilliporeSigma’s EX-CELL® Advanced™ HD Perfusion Medium meets “next-gen” manufacturing requirements, allowing customers to achieve a more optimal output than they would using conventional batch or fed-batch processes.
“This launch is a major milestone on the road to truly enabling next generation processing,” said Udit Batra, CEO, MilliporeSigma. “The benefits of perfusion technology include increased cost efficiency, decreased risk and enhanced manufacturing flexibility—ultimately advancing our customers’ production capabilities and increasing access to therapies for people worldwide.”
A benefit of perfusion processing is higher protein yields, compared with fed-batch, which has been the primary mammalian cell cultivation mode for biopharma manufacturing over the past few decades. Perfusion technology is compatible with small portable plants and can be used with many drug types over a range of production scales.
MilliporeSigma’s EX-CELL® Advanced™ HD Perfusion Medium is the most recent addition to the company’s EX-CELL® Advanced™ product line, which offers increased performance, streamlines regulatory compliance and provides the supply chain security needed in today’s evolving biopharmaceutical environment.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany today announced the opening of a M Lab™ Collaboration Center in Shanghai, the largest of nine centers worldwide operated by the company’s Life Science business.